Editorial Material
Oncology
Sun Min Lim, Chang Gon Kim, Byoung Chul Cho
Summary: Treatment resistance to targeted agents is a significant challenge in cancer therapy and is also observed in EGFR-mutant NSCLC. Current efforts focus on delaying or overcoming acquired resistance, and targeting compensatory feedback loops along with oncogenic signaling pathways holds promise for improved outcomes.
Article
Cell Biology
Ke-Ren Zhang, Yu-Fei Zhang, Hui-Min Lei, Ya-Bin Tang, Chun-Shuang Ma, Qian-Ming Lv, Shi-Yi Wang, Li-Ming Lu, Ying Shen, Hong-Zhuan Chen, Liang Zhu
Summary: The study uncovered a metabolic mechanism driving resistance to EGFR TKIs by promoting cystine metabolism, and suggested AKR1B1 as a potential therapeutic target to overcome resistance to EGFR TKIs.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Biophysics
Parimala Devi Ganthala, Sateesh Alavala, Naveen Chella, Sai Balaji Andugulapati, Nagendra Babu Bathini, Ramakrishna Sistla
Summary: Erlotinib-based EGFR targeted therapy has shown significant clinical improvement against non-small cell lung cancer. However, the development of drug resistance limits its effectiveness. In this study, the combination of Erlotinib and Quercetin was found to be more synergistic against certain lung cancer cells compared to other natural products. By preparing drug-loaded nanoparticles, the encapsulation efficiency and release performance of the drugs were improved. The nanoparticles could reduce the expression of drug-resistant proteins, increase drug uptake, and induce apoptosis in drug-resistant cells. In vivo experiments also showed increased uptake of nanoparticles in lung tissue and decreased expression of cancer-related genes.
COLLOIDS AND SURFACES B-BIOINTERFACES
(2022)
Article
Multidisciplinary Sciences
Mari Tone, Kota Iwahori, Takayuki Shiroyama, Shinji Futami, Yujiro Naito, Kiyoharu Fukushima, Kotaro Miyake, Shohei Koyama, Haruhiko Hirata, Izumi Nagatomo, Hisashi Wada, Yoshito Takeda, Atsushi Kumanogoh
Summary: Minocycline administration in NSCLC patients treated with first-line EGFR-TKIs was found to correlate with longer PFS and OS, independent of skin rash. This retrospective analysis suggests that minocycline may have a positive impact on the treatment outcomes of EGFR-mutant NSCLC patients.
SCIENTIFIC REPORTS
(2023)
Article
Pharmacology & Pharmacy
Cong Xu, Ze-Bo Jiang, Le Shao, Zi-Ming Zhao, Xing-Xing Fan, Xinbing Sui, Li-Li Yu, Xuan-Run Wang, Ruo-Nan Zhang, Wen-Jun Wang, Ya-Jia Xie, Yi-Zhong Zhang, Xiao-Wen Nie, Chun Xie, Ju-Min Huang, Jing Wang, Jue Wang, Elaine Lai-Han Leung, Qi-Biao Wu
Summary: This study found that the combination of ll-elemene and erlotinib induced ferroptosis and enhanced the sensitivity to EGFR-TKIs in EGFR-TKI-resistant lung cancer patients.
PHARMACOLOGICAL RESEARCH
(2023)
Article
Oncology
Carolin Selenz, Anik Compes, Marieke Nill, Sven Borchmann, Margarete Odenthal, Alexandra Florin, Johannes Braegelmann, Reinhard Buettner, Lydia Meder, Roland T. Ullrich
Summary: EGFR inhibition promotes immune cell infiltration in the tumour microenvironment and enhances response to immune checkpoint inhibitors in EGFR-driven lung cancer.
Article
Engineering, Biomedical
Duo Wang, Jun Zhou, Weimin Fang, Cuiqing Huang, Zerong Chen, Meng Fan, Ming-Rong Zhang, Zeyu Xiao, Kuan Hu, Liangping Luo
Summary: In this study, a multifunctional superparamagnetic nanotheranostic agent was developed to enhance the efficacy of Erlotinib in EGFR-wt NSCLC. The nanoparticles co-delivered Erlotinib and a VEGF inhibitor (Bev) to EGFR-wt tumors, inhibiting tumor growth and promoting vascular normalization. The tumor engagement of nanoparticles and vascular normalization could be tracked by MRI.
BIOACTIVE MATERIALS
(2022)
Article
Pharmacology & Pharmacy
Po-Yen Chen, Chin-Chou Wang, Chien-Ning Hsu, Chung-Yu Chen
Summary: This study compared the relative survival rate of gefitinib, erlotinib, and afatinib in EGFR-mutated advanced lung adenocarcinoma patients in Taiwan. Afatinib showed better overall survival and time to treatment failure outcomes compared to gefitinib and erlotinib, especially in patients with initial brain metastases.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Multidisciplinary Sciences
Chia- Shen, Chi-Lu Chiang, Tsu-Hui Shiao, Yung-Hung Luo, Heng-Sheng Chao, Hsu-Ching Huang, Chao-Hua Chiu
Summary: Detection of driver gene mutations is crucial in advanced NSCLC. The cobas EGFR mutation test has limitations due to its primer design, while next-generation sequencing-based assay provides a higher mutation detection coverage. Comprehensive genomic profiling can identify EGFR mutations missed by the cobas test and offers significant benefits to patients with NSCLC.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Alexis B. Cortot, Anne Madroszyk, Etienne Giroux-Leprieur, Olivier Molinier, Elisabeth Quoix, Henri Berard, Josiane Otto, Isabelle Rault, Denis Moro-Sibilot, Judith Raimbourg, Elodie Amour, Franck Morin, Jose Hureaux, Lionel Moreau, Didier Debieuvre, Hugues Morel, Aldo Renault, Eric Pichon, Benjamin Huret, Sandrine Charpentier, Marc G. Denis, Jacques Cadranel
Summary: The addition of cetuximab to afatinib in the treatment of treatment-naive advanced EGFR-mutant NSCLC did not show any significant improvement in efficacy, suggesting that further investigation into this combination therapy may not be warranted.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Hirohito Tada, Tetsuya Mitsudomi, Toshihiro Misumi, Kenji Sugio, Masahiro Tsuboi, Isamu Okamoto, Yasuo Iwamoto, Noriaki Sakakura, Shunichi Sugawara, Shinji Atagi, Toshiaki Takahashi, Hidetoshi Hayashi, Morihito Okada, Hidetoshi Inokawa, Hiroshige Yoshioka, Kazuhisa Takahashi, Masahiko Higashiyama, Ichiro Yoshino, Kazuhiko Nakagawa
Summary: The efficacy of gefitinib as an adjuvant therapy for non-small-cell lung cancer patients with EGFR mutation was investigated in this study. The results showed that although gefitinib appeared to prevent early relapse, it did not prolong disease-free survival or overall survival. However, in certain patient subsets, adjuvant gefitinib may be justified.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Chemistry, Medicinal
Chih-Hung Guo, Wen-Chin Li, Chia-Lin Peng, Pei-Chung Chen, Shih-Yu Lee, Simon Hsia
Summary: This study found that the combination of selenium/fish oil with gefitinib or erlotinib significantly reduced tumor volume and weight in lung cancer treatment, and also reduced metastasis. Furthermore, the combination treatment modulated multiple signaling pathways and immune checkpoint molecules, reduced angiogenesis, cancer stemness, epithelial to mesenchymal transitions, metastasis, and proliferation, and increased cell cycle arrest and apoptosis.
Article
Oncology
James Chih-Hsin Yang, Yuichiro Ohe, Chao -Hua Chiu, Xiaoling Ou, Mireille Cantarini, Pasi A. Janne, Ryan J. Hartmaier, Myung Ju Ahn
Summary: The combination of osimertinib and selumetinib showed promising antitumor activity and tolerability in patients with MET-negative, EGFRm advanced NSCLC who had progressed on previous EGFR-TKI treatment.
CLINICAL CANCER RESEARCH
(2022)
Article
Multidisciplinary Sciences
Chie Morita, Tatsuya Yoshida, Masayuki Shirasawa, Ken Masuda, Yuji Matsumoto, Yuki Shinno, Shigehiro Yagishita, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Noriko Motoi, Yasushi Yatabe, Yuichiro Ohe
Summary: Patients with Exon20ins mutations and major mutations had similar clinical characteristics, but Exon20ins patients had less satisfactory clinical outcomes compared to M-mut patients.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
R. B. Verheijen, T. T. van Duijl, M. M. van den Heuvel, D. Vessies, M. Muller, J. H. Beijnen, J. M. Janssen, J. H. M. Schellens, N. Steeghs, D. van den Broek, A. D. R. Huitema
Summary: EGFR mutations in circulating tumor DNA were quantified in 249 plasma samples from 68 NSCLC patients, showing driver mutations increased in copy number several months before disease progression. Quantification of EGFR mutations in plasma ctDNA was predictive of treatment outcomes in NSCLC patients, particularly an increase in driver mutation copy number could predict disease progression.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Sergey N. Fedosov, Ebba Nexo, Christian W. Heegaard
Summary: Vitamin B12 exists in different molecular variants, among which MeCbl is usually not detected in tissue samples. We hypothesized that this is due to degradation or conversion caused by harsh extraction methods. By using a mild extraction protocol, we found a relatively high content of MeCbl in rat liver.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
(2023)
Editorial Material
Nutrition & Dietetics
Ali Niklewicz, A. David Smith, Alison Smith, Andre Holzer, Andrew Klein, Andrew McCaddon, Anne M. Molloy, Bruce H. R. Wolffenbuttel, Ebba Nexo, Helene McNulty, Helga Refsum, Jean-Louis Gueant, Marie-Joe Dib, Mary Ward, Michelle Murphy, Ralph Green, Kourosh R. Ahmadi, Luciana Hannibal, Martin J. Warren, P. Julian Owen
Summary: Vitamin B-12 deficiency is common among vegetarians and vegans, especially pregnant women or women of child-bearing age. It is associated with increased risk of neuro, vascular, immune, and inflammatory disorders. However, the current recommended nutrient intake for vitamin B-12 does not adequately consider the needs of individuals choosing a plant-based diet.
EUROPEAN JOURNAL OF NUTRITION
(2023)
Article
Medicine, General & Internal
Yanni Li, Kristina Sundquist, Naiqi Zhang, Xiao Wang, Jan Sundquist, Ashfaque A. Memon
Summary: This study used genetic instruments to investigate the causal relationship between mitochondrial dysfunction and multiple cancers. It identified potential candidate genes for cancer prevention and treatment.
Article
Oncology
Christoffer T. Maansson, Sofie Helstrup, Eva B. F. Ebert, Peter Meldgaard, Boe S. Sorensen
Summary: This study discovers novel circulating biomarkers that can predict the overall survival after progressive disease (PD) on osimertinib treatment in non-small-cell lung cancer patients with EGFR mutations. The altered expression of immune system-related proteins at PD provides insight into osimertinib resistance.
TRANSLATIONAL LUNG CANCER RESEARCH
(2023)
Article
Oncology
Judit Kisistok, Ditte Sigaard Christensen, Mads Heilskov Rasmussen, Lone Duval, Ninna Aggerholm-Pedersen, Adam Andrzej Luczak, Boe Sandahl Sorensen, Martin Roelsgaard Jakobsen, Trine Heide Oellegaard, Nicolai Juul Birkbak
Summary: Immunotherapy has dramatically improved the treatment outcomes for metastatic melanoma patients, but it also brings immune-related adverse events. Identifying nonresponding patients early is crucial, and this study explores the use of circulating tumor DNA (ctDNA) analysis as a minimally invasive tool. In a cohort of 24 melanoma patients, the presence of ctDNA was associated with poor prognosis, suggesting its potential to be used in clinical practice.
Article
Oncology
Christoffer Trier Maansson, Peter Meldgaard, Magnus Stougaard, Anders Lade Nielsen, Boe Sandahl Sorensen
Summary: Cell-free chromatin immunoprecipitation (cfChIP) of H3K36me3-modified nucleosomes in blood plasma can be used to determine tumor gene expression levels. In this study, cfChIP-seq was performed on blood plasma samples from lung cancer patients and healthy controls. The results showed increased enrichment of mutated alleles in plasma from patients with somatic cancer mutations, and concordant H3K36me3 cfChIP enrichment profiles in different lung cancer types. These findings demonstrate the utility of cfDNA in liquid biopsies for characterizing cancer and predicting disease progression.
MOLECULAR ONCOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Sakshi Vats, Kristina Sundquist, Yanni Li, Xiao Wang, Mun-Gwan Hong, Jan Sundquist, Moncef Zarrouk, Anders Gottsater, Ashfaque A. Memon
Summary: This study for the first time investigated the mitochondrial genome in AAA and identified important genetic alterations and haplogroups associated with AAA and clinical risk factors. These findings have the potential to fill in gaps in the missing genetic information on AAA.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Article
Oncology
Trine V. Larsen, Nina Dybdal, Tina F. Daugaard, Johanne Lade-Keller, Lin Lin, Boe S. Sorensen, Anders L. Nielsen
Summary: This study investigates the role of PD-L1 DNA methylation in regulating and predicting PD-L1 expression in non-small-cell lung cancer (NSCLC) patients undergoing immunotherapy. The analysis of tumor biopsies and cell lines reveals that PD-L1 DNA methylation status influences its expression. However, the correlation between methylation and expression is weak in NSCLC tumor samples. This study emphasizes the importance of further research to improve the effectiveness of PD-1/PD-L1 immunotherapy in NSCLC.
Article
Oncology
Simone Stensgaard, Astrid Thomsen, Sofie Helstrup, Peter Meldgaard, Boe S. Sorensen
Summary: In this study, the researchers investigated whether circulating tumor DNA (ctDNA) could predict response to pembrolizumab in patients with non-small cell lung cancer (NSCLC). The results showed that high blood tumor mutational burden (bTMB) was associated with longer progression-free survival (PFS) and overall survival (OS). Moreover, an increase in ctDNA levels after treatment initiation was significantly correlated with inferior survival.
TRANSLATIONAL LUNG CANCER RESEARCH
(2023)
Article
Behavioral Sciences
Marie Vadstrup Pedersen, Line Mathilde Brostrup Hansen, Ben Garforth, Paul J. Zak, Michael Winterdahl
Summary: This study compared the HPA axis response to stress in women using oral contraceptives (OCs) and naturally cycling (NC) women. It found that unlike NC women, OC users did not show a decrease in ACTH levels during social interaction. This study highlights the impact of OC use on stress regulation and emphasizes the importance of considering hormonal contraceptive use and menstrual cycle phases when evaluating female stress responses.
BEHAVIOURAL BRAIN RESEARCH
(2023)
Article
Oncology
Signe Neldeborg, Johannes Frasez Soerensen, Charlotte Thornild Moller, Marie Bill, Zongliang Gao, Rasmus O. Bak, Kasper Holm, Boe Sorensen, Mette Nyegaard, Yonglun Luo, Peter Hokland, Magnus Stougaard, Maja Ludvigsen, Christian Kanstrup Holm
Summary: Oncogenic fusion drivers in hematological cancers can be targeted using a new dual intron-targeting CRISPR-Cas9 treatment strategy. This strategy can efficiently disrupt fusion genes without requiring precise knowledge of the breakpoints in t(8;21) AML. In vitro and in vivo experiments showed significant reduction in cell growth and tumor growth in response to disruption of RUNX1-RUNX1T1. These findings were confirmed in primary cells from an AML patient.
Article
Oncology
Sara Bonlokke, Torben Steiniche, Boe Sandahl Sorensen, Gitte-Bettina Nyvang, Jacob Christian Lindegaard, Jan Blaakaer, Jesper Bertelsen, Katrine Fuglsang, Mikael Lenz Strube, Suzan Lenz, Magnus Stougaard
Summary: This study demonstrates the association between circulating cell-free HPV DNA (ccfHPV) and disease severity in cervical cancer. HPV integration status is also correlated with viral load and survival. The findings suggest that ccfHPV presence may contribute to the identification of patients suitable for adjuvant oncological therapy.
MOLECULAR ONCOLOGY
(2023)
Article
Hematology
Xiao Wang, Ashfaque A. Memon, Anna Hedelius, Anton Grundberg, Johan L. Elf, Peter J. Svensson, Jan Sundquist, Kristina Sundquist
Summary: Mitochondrial dysfunction is a known factor in the development of deep vein thrombosis (DVT). This study aimed to investigate the potential role of 7S RNA, a long noncoding RNA that plays a role in mitochondrial function, in DVT. The findings showed a significant decrease in plasma expression of 7S RNA in DVT patients, suggesting it may serve as a biomarker for DVT.
SEMINARS IN THROMBOSIS AND HEMOSTASIS
(2023)
Article
Nutrition & Dietetics
Victor Nikiema, Suvi T. Kangas, Cecile Salpeteur, Andre Briend, Leisel Talley, Henrik Friis, Christian Ritz, Ebba Nexo, Adrian Mccann
Summary: In children with severe acute malnutrition, treatment with RUTF improved B12 status but did not fully correct deficiency. Breastfed children had lower B12 status compared to non-breastfed children.
Article
Cardiac & Cardiovascular Systems
Sakshi Vats, Kristina Sundquist, Jan Sundquist, Naiqi Zhang, Xiao Wang, Stefan Acosta, Anders Gottsater, Ashfaque A. Memon
Summary: The study investigates the impact of genetic variations in genes related to oxidative stress, intake of antioxidant vitamins, and potential interactions on abdominal aortic aneurysm (AAA) and its rupture. Results show that a variant in NOX3 is associated with increased risk of AAA and rupture. Higher intake of antioxidant vitamins, riboflavin, and folate are associated with reduced incidence of AAA. The relationship between riboflavin and vitamin B12 intake and AAA risk is modified by sex.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2023)
